Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran …
Background Stroke is the most serious clinical consequence of atrial fibrillation, which is the
most common cardiac arrhythmia. Non-vitamin K antagonist oral anticoagulants (NOACs) …
most common cardiac arrhythmia. Non-vitamin K antagonist oral anticoagulants (NOACs) …
Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic …
The non-vitamin K antagonist oral anticoagulants (NOACs) have been increasingly
prescribed in clinical practice for stroke prevention in patients with nonvalvular atrial …
prescribed in clinical practice for stroke prevention in patients with nonvalvular atrial …
The efficacy and safety of oral anticoagulants in warfarin-suitable patients with nonvalvular atrial fibrillation: systematic review and meta-analysis
SA Mitchell, TA Simon, S Raza… - Clinical and applied …, 2013 - journals.sagepub.com
The novel oral anticoagulants (NOACs) apixaban, dabigatran, and rivaroxaban have been
recently indicated for stroke prevention in patients with atrial fibrillation (AF). Due to a lack of …
recently indicated for stroke prevention in patients with atrial fibrillation (AF). Due to a lack of …
Real-world evidence comparing oral anticoagulants in non-valvular atrial fibrillation: a systematic review and network meta-analysis
S Deitelzweig, E Bergrath, M di Fusco, A Kang… - Future …, 2022 - Taylor & Francis
Aim: To compare real-world effectiveness/safety of non-vitamin K antagonist oral
anticoagulants and vitamin K antagonists among patients with non-valvular atrial fibrillation …
anticoagulants and vitamin K antagonists among patients with non-valvular atrial fibrillation …
Safety and efficacy of non-vitamin K oral anticoagulants in non-valvular atrial fibrillation: a Bayesian meta-analysis approach
P Verdecchia, F Angeli, C Bartolini… - Expert Opinion on …, 2015 - Taylor & Francis
Introduction: Choosing between different non-vitamin K antagonist oral anticoagulants
(NOACs) in non-valvular atrial fibrillation (NVAF) is difficult due to the absence of head to …
(NOACs) in non-valvular atrial fibrillation (NVAF) is difficult due to the absence of head to …
Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation: a systematic …
G Ntaios, V Papavasileiou, K Makaritsis, K Vemmos… - Stroke, 2017 - Am Heart Assoc
Background and Purpose—Evidence from the real-world setting complements evidence
coming from randomized controlled trials. We aimed to summarize all available evidence …
coming from randomized controlled trials. We aimed to summarize all available evidence …
[HTML][HTML] Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: a network meta-analysis with the adjustment for the possible bias …
T Morimoto, B Crawford, K Wada, S Ueda - Journal of Cardiology, 2015 - Elsevier
Background This study was designed to compare efficacy and safety among novel oral
anticoagulants (NOACs), which have not been directly compared in randomized control …
anticoagulants (NOACs), which have not been directly compared in randomized control …
Safety and efficacy of direct acting oral anticoagulants and vitamin K antagonists in nonvalvular atrial fibrillation–a network meta-analysis of real-world data
M Hirschl, M Kundi - Vasa, 2018 - econtent.hogrefe.com
Background: In randomized controlled trials (RCTs) direct acting oral anticoagulants
(DOACs) showed a superior risk-benefit profile in comparison to vitamin K antagonists …
(DOACs) showed a superior risk-benefit profile in comparison to vitamin K antagonists …
Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings
LA de Jong, J Groeneveld, J Stevanovic, H Rila… - PLoS …, 2019 - journals.plos.org
Introduction Randomized clinical trials (RCTs) and real-world data (RWD) in patients with
atrial fibrillation have shown that—compared to vitamin K antagonists (VKAs)—non-VKA oral …
atrial fibrillation have shown that—compared to vitamin K antagonists (VKAs)—non-VKA oral …
Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation
NW Andersson, H Svanström, M Lund… - International journal of …, 2018 - Elsevier
Background The comparative effectiveness and safety of individual direct oral
anticoagulants (DOACs) in clinical practice is largely unknown. The study objectives were to …
anticoagulants (DOACs) in clinical practice is largely unknown. The study objectives were to …
相关搜索
- meta analysis oral anticoagulants
- meta analysis stroke prevention
- meta analysis atrial fibrillation
- safety of apixaban rivaroxaban in patients
- safety and efficacy oral anticoagulants
- atrial fibrillation oral anticoagulants
- patient subgroups relative efficacy
- meta analysis patient subgroups
- meta analysis relative efficacy
- stroke prevention oral anticoagulants
- atrial fibrillation stroke prevention
- setting comparison oral anticoagulants
- atrial fibrillation setting comparison
- meta analysis setting comparison
- atrial fibrillation real world
- atrial fibrillation cost effectiveness